Linearis Opened its New Laboratory Offering an AI Biomarkers Analytical Platform for Innovation Against Cancer, Diabetes, Antimicrobial Resistance, and Other Metabolic Diseases
Retrieved on:
Tuesday, November 28, 2023
Université de Montréal, Press Conference (TV program), Mass spectrometry, AP-HP, IRIC, Université Laval, Acceleration, INAF, Medicago Inc., Biotechnology, DSM-IV codes, TMIC, Medicine, McGill University, Conference, Voltigeur, University, Drug discovery, FRQ, Cancer, Biomarker, AI, Diabetes, Metabolomics, University of Ottawa, Medical device, Pharmaceutical industry, Chomatodus, Operation Axe, Medicago
Leveraging artificial intelligence (AI), Linearis provides a comprehensive health status based on the analysis of 1,400 metabolomic biomarkers through mass spectrometry.
Key Points:
- Leveraging artificial intelligence (AI), Linearis provides a comprehensive health status based on the analysis of 1,400 metabolomic biomarkers through mass spectrometry.
- The platform will enable its clients to improve prevention, screening, treatment monitoring, and new drug discovery.
- The combination of AI and high-throughput automated analysis of 1,400 metabolomic biomarkers enables Linearis to better identify numerous elements associated with metabolic diseases including cancer, diabetes, and antimicrobial resistance.
- "We are grateful for the support from Medicago during this transaction enabling the creation of this innovative and collaborative laboratory.